Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (631-640 of 671) with videos related to

Pageof 68
Sort By:
Blood Advances|April 3, 2020
Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entityAnkur Varma, Susan C Abraham, Rohtesh S Mehta, et al.
Cancer|May 6, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapyJennifer Marvin-Peek, Courtney D DiNardo, Sanam Loghavi, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Blood|July 2, 2015
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemiaStefan O Ciurea, Mei-Jie Zhang, Andrea A Bacigalupo, et al.
Cancer|July 13, 2016
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationSameh Gaballa, Isabell Ge, Riad El Fakih, et al.
The Lancet. Haematology|March 27, 2019
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trialQaiser Bashir, Peter F Thall, Denái R Milton, et al.
Transplantation and Cellular Therapy|September 19, 2021
Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Leonard C Alsfeld, et al.
Bone Marrow Transplantation|May 6, 2022
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myelomaMahmoud R Gaballa, Junsheng Ma, Mikael Rauf, et al.
The Lancet. Haematology|November 4, 2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trialUday R Popat, Rohtesh S Mehta, Roland Bassett, et al.
Leukemia|January 1, 1996
Chemotherapy versus transplants for acute myelogenous leukemia in second remissionR P Gale, M M Horowitz, J K Rees, et al.
Pageof 68

Showing results (631-640 of 671) with videos related to

Sort By:
Pageof 68
Blood Advances|April 3, 2020
Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entityAnkur Varma, Susan C Abraham, Rohtesh S Mehta, et al.
Cancer|May 6, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapyJennifer Marvin-Peek, Courtney D DiNardo, Sanam Loghavi, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Blood|July 2, 2015
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemiaStefan O Ciurea, Mei-Jie Zhang, Andrea A Bacigalupo, et al.
Cancer|July 13, 2016
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationSameh Gaballa, Isabell Ge, Riad El Fakih, et al.
The Lancet. Haematology|March 27, 2019
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trialQaiser Bashir, Peter F Thall, Denái R Milton, et al.
Transplantation and Cellular Therapy|September 19, 2021
Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Leonard C Alsfeld, et al.
Bone Marrow Transplantation|May 6, 2022
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myelomaMahmoud R Gaballa, Junsheng Ma, Mikael Rauf, et al.
The Lancet. Haematology|November 4, 2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trialUday R Popat, Rohtesh S Mehta, Roland Bassett, et al.
Leukemia|January 1, 1996
Chemotherapy versus transplants for acute myelogenous leukemia in second remissionR P Gale, M M Horowitz, J K Rees, et al.
Pageof 68